Early apremilast initiation is associated with reduced psoriasis activity and burden compared with late initiation or continued topical therapy use.

A slightly more premium option, and one that includes the same colloidal oatmeal as the Aveeno cream above, Dr Armstrong ...

Johnson & Johnson's Q3 2025 earnings beat forecasts, with strong oncology sales and raised guidance. Click for my updated ...

Johnson & Johnson raises 2025 sales forecast and beats quarterly estimates, while announcing plans to spin off its $9.2 ...

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion ...

Find insight on Johnson & Johnson, Japanese pharmaceutical stocks and more in the latest Market Talks covering the health ...

Topicals are often the first-line treatment for psoriasis, but as the condition progresses, you may need to consider systemic treatments to manage your symptoms. Here’s what to know about your options ...

Good morning, and welcome to Johnson & Johnson's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded. [Operator Instructions] I will now turn the ...

We reviewed dozens of studies and spoke with researchers to find out whether any supplements demonstrate anti-inflammatory ...

The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis ...

Johnson & Johnson (NYSE: JNJ) has released its financial results for the third quarter of 2025, showing notable growth in ...